Olezarsen vs Plozasiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Familial Chylomicronemia Syndrome

Shared mechanism: APOC3 · full Familial Chylomicronemia Syndrome pipeline

Olezarsen · Tryngolza

Marketed by Ionis Pharmaceuticals and partners

Approved in Familial Chylomicronemia Syndromeantisense oligonucleotide
Partial signal

NCT04568434 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 66 patients with a rare disease. Of its two primary comparisons, olezarsen 80 mg lowered triglycerides significantly more than placebo at 6 months (p=0.0009), but olezarsen 50 mg did not (p=0.0775), so the primary result was only partly met.

Next expected readout: June 2027 · NCT05185843 (registry estimate)

Reported efficacy

Percent Change From Baseline in Fasting TG at Month 6: Fasting triglycerides, percent change at 6 months vs placebo: olezarsen 80 mg -43.5 percentage points (95% CI -69.1 to -17.9), P<0.001 (met); olezarsen 50 mg -22.4 percentage points (95% CI -47.2 to 2.5), P = 0.08 (not met). Acute pancreatitis: 11 episodes on placebo vs 1 in each olezarsen group by week 53. (mixed)

Result source: NCT04568434

Plozasiran · Redemplo

Marketed by Arrowhead Pharmaceuticals and partners

Approved in Familial Chylomicronemia SyndromeRNAi (siRNA)
Partial signal

NCT05089084 · Phase 3 · completed

The study randomly assigned 75 participants to plozasiran or placebo and used quadruple masking, with 25 mg, 50 mg, and pooled placebo groups. The primary fasting-triglyceride endpoint was statistically significantly improved for both doses, but it was a laboratory surrogate rather than a hard clinical or endoscopic outcome, supporting a moderate grade.

Reported efficacy

Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): ARO-APOC3 (Plozasiran) 25 mg -80.1% (IQR -89.9 to -61) | ARO-APOC3 (Plozasiran) 50 mg -77.6% (IQR -87.7 to -48.6) vs Placebo (Pooled) -17.1% (IQR -49.1 to 47) (met)

Result source: NCT05089084

Results for Familial Chylomicronemia Syndrome

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Olezarsen
Fasting triglycerides, percent change at 6 months vs placebo: olezarsen 80 mg -43.5 percentage points (95% CI -69.1 to -17.9), P<0.001 (met); olezarsen 50 mg -22.4 percentage points (95% CI -47.2 to 2.5), P = 0.08 (not met). Acute pancreatitis: 11 episodes on placebo vs 1 in each olezarsen group by week 53. NCT04568434 · Phase 3 · design grade: moderate · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Plozasiran

Triglycerides -80.1% (n=24) vs -17.1% (n=19) placebo @ 40wk25 mg
percent change · % of baseline
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 5 more results
-77.7% (n=24) vs -2.6% (n=19) placebo25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
-61.5% (n=26) vs 0.72% (n=25) placebo @ 48wk25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
-77.6% (n=22) vs -17.1% (n=19) placebo @ 40wk50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
-71% (n=22) vs -2.6% (n=19) placebo50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
-45.38% (n=24) vs 0.72% (n=25) placebo @ 48wk50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
Non-HDL-C -38.69% (n=26) vs 3.67% (n=25) placebo @ 40wk25 mg
percent change · % of baseline
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 3 more results
-38.16% (n=26) vs 6.72% (n=25) placebo @ 48wk25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
-36.12% (n=24) vs 3.67% (n=25) placebo @ 40wk50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
-25.48% (n=24) vs 6.72% (n=25) placebo @ 48wk50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
HDL-C 65.48% (n=26) vs 2.89% (n=25) placebo @ 40wk25 mg
percent change · % of baseline
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 3 more results
61.9% (n=26) vs 20.61% (n=25) placebo @ 48wk25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
72.02% (n=24) vs 2.89% (n=25) placebo @ 40wk50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
74.52% (n=24) vs 20.61% (n=25) placebo @ 48wk50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
Available safety results

Plozasiran

Dropout rate
11.5%25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 1 more result
8.3%50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
Discontinued due to AEs
7.7%25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 1 more result
4.2%50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
Serious AEs
19.2%25 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 1 more result
8.3%50 mg
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
Most frequent reported AEs
25 mg
abdominal pain 26.9% (placebo 28%)
covid-19 19.2% (placebo 4%)
nasopharyngitis 19.2% (placebo 16%)
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3
show 1 more result
50 mg
abdominal pain 29.2% (placebo 28%)
covid-19 29.2% (placebo 4%)
headache 20.8% (placebo 8%)
NCT05089084 · Phase 3 · monotherapy · Familial Chylomicronemia Syndrome · phase 3

Severe Hypertriglyceridemia

Shared mechanism: APOC3 · full Severe Hypertriglyceridemia pipeline

Olezarsen · Tryngolza

Marketed by Ionis Pharmaceuticals and partners

Approved in Severe Hypertriglyceridemiaantisense oligonucleotide
Reliable signal

NCT05079919 · Phase 3 · completed

This was a randomized, triple-blind, placebo-controlled trial of 617 patients. Both tested doses of olezarsen produced large reductions in triglycerides, the physiological measure that defines this disease, compared with placebo, with strong statistical significance.

Next expected readout: March 2027 · NCT05681351 (registry estimate)

Reported efficacy

Percent Change from Baseline in Fasting TG Compared to Placebo (Baseline and Month 6): Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) (met)

Result source: NCT05552326

Plozasiran · Redemplo

Marketed by Arrowhead Pharmaceuticals and partners

Phase 3 in Severe HypertriglyceridemiaRNAi (siRNA)
Partial signal

NCT06347003 · Phase 3 · completed

This was a randomized, quadruple-masked Phase 3 trial with 446 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-07-22. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: March 2029 · NCT06880770 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Severe Hypertriglyceridemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Olezarsen: 8 of 9 rows · Plozasiran: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOlezarsenPlozasiran
Apo B
percent change · % of baseline
-11.67% (n=58) vs 0.68% (n=39) placebo @ 52wk50 mga,b,c,d
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more dose
-18.53% (n=57) vs 0.68% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
2.4% (n=57) vs 5.7% (n=60) placebo @ 48wk50 mga,b,c,d
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more doses
-0.2% (n=55) vs 5.7% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
6.4% (n=54) vs 5.7% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Apo C3
percent change · % of baseline
-69.09% (n=58) vs -12.4% (n=39) placebo @ 52wk50 mga,b,c,d
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more dose
-83.78% (n=57) vs -12.4% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-48.3% (n=57) vs 135.8% (n=60) placebo @ 48wk50 mga,b,c,d
NCT04720534 · Phase 2 · registry result, not featured evidence
show 5 more doses
-46.8% (n=57) vs 5.6% (n=57) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-49.6% (n=55) vs 135.8% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-48% (n=55) vs 5.6% (n=57) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-34.5% (n=54) vs 135.8% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-33.7% (n=53) vs 5.6% (n=57) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Fasting TG
percent change · % of baseline
-51.67% (n=58) vs -5.59% (n=39) placebo @ 52wk50 mga,b,c,d
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more dose
-60.39% (n=57) vs -5.59% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-53.4% (n=57) vs -6.6% (n=60) placebo @ 48wk50 mga,b,c,d
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more doses
-58% (n=55) vs -6.6% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-31.4% (n=54) vs -6.6% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
HDL-C
percent change · % of baseline
54.2% (n=58) vs 10.53% (n=39) placebo @ 52wk50 mga,b,c,d
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more dose
57.43% (n=57) vs 10.53% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
37.8% (n=57) vs 6.1% (n=60) placebo @ 48wk50 mga,b,c,d
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more doses
32.4% (n=55) vs 6.1% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
23.5% (n=54) vs 6.1% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Non-HDL-C
percent change · % of baseline
-20% (n=58) vs -2.55% (n=39) placebo @ 52wk50 mga,b,c,d
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more dose
-26.57% (n=57) vs -2.55% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-13.5% (n=57) vs 0.5% (n=60) placebo @ 48wk50 mga,b,c,d
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more doses
-23% (n=55) vs 0.5% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-10% (n=54) vs 0.5% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Dropout rate
12.1%50 mge
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more result
8.8%80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
7%50 mge
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more results
5.5%25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
9.1%10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—50 mge
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more result
—80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
1.8%50 mge
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more results
0%25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
1.8%10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Serious AEs
10.3%50 mge
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more result
14%80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
12.5%50 mge
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more results
3.6%25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
7.4%10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
50 mge
injection site erythema 13.8% (placebo 0%)
fatigue 10.3% (placebo 2.6%)
urinary tract infection 10.3% (placebo 15.4%)
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more result
80 mg
covid-19 7% (placebo 5.1%)
diabetes mellitus 7% (placebo 2.6%)
acute sinusitis 5.3% (placebo 2.6%)
NCT05355402 · Phase 2 · registry result, not featured evidence
50 mge
covid-19 16.1% (placebo 14.8%)
upper respiratory tract infection 12.5% (placebo 6.6%)
type 2 diabetes mellitus 10.7% (placebo 4.9%)
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more results
25 mg
covid-19 16.4% (placebo 14.8%)
headache 10.9% (placebo 4.9%)
sinusitis 7.3% (placebo 0%)
NCT04720534 · Phase 2 · registry result, not featured evidence
10 mg
covid-19 20.4% (placebo 14.8%)
headache 14.8% (placebo 4.9%)
urinary tract infection 11.1% (placebo 9.8%)
NCT04720534 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 48 weeks versus 52 weeks.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olezarsen

Fasting TG Less Than 150 mg/dL 79.2% (n=53) vs 11.4% (n=35) placebo @ 26wk50 mg
responder rate · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
69.8% (n=53) vs 5.7% (n=35) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
84% (n=50) vs 11.4% (n=35) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
82% (n=50) vs 5.7% (n=35) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Remnant Cholesterol -55.98% (n=58) vs -9.46% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-58.17% (n=58) vs -14.83% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-59.59% (n=57) vs -9.46% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-66.9% (n=57) vs -14.83% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Apo A1 17.37% (n=58) vs 2.84% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
16.37% (n=58) vs 0.81% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
14.91% (n=57) vs 2.84% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
15.46% (n=57) vs 0.81% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Total Cholesterol -6.78% (n=58) vs 2.99% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-6.08% (n=58) vs -2.15% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-6.48% (n=57) vs 2.99% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-10.8% (n=57) vs -2.15% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Fasting TG Less Than 500 mg/dL 80% (n=5) vs 75% (n=4) placebo @ 26wk50 mg
responder rate · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
100% (n=5) vs 75% (n=4) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
100% (n=7) vs 75% (n=4) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
100% (n=7) vs 75% (n=4) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Acute Pancreatitis 0% (n=58) vs 0% (n=39) placebo @ 52wk50 mg
event count · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 3 more results
0% (n=58) vs 0% (n=39) placebo @ 52wk*50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=57) vs 0% (n=39) placebo @ 52wk*80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=57) vs 0% (n=39) placebo @ 52wk*80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
Fasting Triglycerides -62.9% @ 25.98wkolezarsen 50 mg
percent change · % of baseline
No placebo or comparator arm
NCT05079919 · Phase 3 · sponsor-reported, not registry data
show 3 more results
-49.2% @ 25.98wkolezarsen 50 mg
NCT05552326 · Phase 3 · sponsor-reported, not registry data
-72.2% @ 25.98wkolezarsen 80 mg
NCT05079919 · Phase 3 · sponsor-reported, not registry data
-54.5% @ 25.98wkolezarsen 80 mg
NCT05552326 · Phase 3 · sponsor-reported, not registry data

Hypertriglyceridemia

Shared mechanism: APOC3 · full Hypertriglyceridemia pipeline

Olezarsen · Tryngolza

Marketed by Ionis Pharmaceuticals and partners

Phase 3 in Hypertriglyceridemiaantisense oligonucleotide
Reliable signal

NCT05610280 · Phase 3 · completed

Essence-TIMI 73b was a large, randomized, double-blind, placebo-controlled trial in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, or with severe hypertriglyceridemia. The primary outcome was the placebo-adjusted percent change in triglycerides from baseline to 6 months in the moderate-hypertriglyceridemia population (1,349 patients). Triglycerides fell by 58.4 percentage points more than placebo with olezarsen 50 mg and by 60.6 percentage points more with 80 mg (P<0.001 for both), so the primary endpoint was met at both doses. The figures come from the peer-reviewed paper (N Engl J Med 2025).

Next expected readout: March 2027 · NCT05681351 (registry estimate)

Reported efficacy

Percent Change from Baseline in Fasting TG Compared to Placebo (Baseline and Month 6): Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) (met)

Result source: NCT05552326

Plozasiran · Redemplo

Marketed by Arrowhead Pharmaceuticals and partners

Phase 3 in HypertriglyceridemiaRNAi (siRNA)
Partial signal

NCT06347003 · Phase 3 · completed

This was a randomized, quadruple-masked Phase 3 trial with 446 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-07-22. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: July 2028 · NCT06822790 (registry estimate)

Reported efficacy

Percent Change in Fasting Serum Triglyceride (TG) Levels from Baseline to Month 12 Compared to Placebo (Baseline, Month 12): Primary endpoint met: triglyceride reduction vs placebo, and all prespecified secondary endpoints (SHASTA-3, Arrowhead, 2026-07-22). (met)

Result source: NCT06347003

Results for Hypertriglyceridemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Coverage. Olezarsen: 9 of 9 rows · Plozasiran: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOlezarsenPlozasiran
Apo B
percent change · % of baseline
-18.53% (n=57) vs 0.68% (n=39) placebo @ 52wk80 mga,b,c,d
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more dose
-11.67% (n=58) vs 0.68% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
2.4% (n=57) vs 5.7% (n=60) placebo @ 48wk50 mga,b,c,d
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more doses
-0.2% (n=55) vs 5.7% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
6.4% (n=54) vs 5.7% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Apo C3
percent change · % of baseline
-83.78% (n=57) vs -12.4% (n=39) placebo @ 52wk80 mga,b,c,d
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more dose
-69.09% (n=58) vs -12.4% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-48.3% (n=57) vs 135.8% (n=60) placebo @ 48wk50 mga,b,c,d
NCT04720534 · Phase 2 · registry result, not featured evidence
show 5 more doses
-46.8% (n=57) vs 5.6% (n=57) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-49.6% (n=55) vs 135.8% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-48% (n=55) vs 5.6% (n=57) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-34.5% (n=54) vs 135.8% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-33.7% (n=53) vs 5.6% (n=57) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Fasting TG
percent change · % of baseline
-60.39% (n=57) vs -5.59% (n=39) placebo @ 52wk80 mga,b,c,d
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more dose
-51.67% (n=58) vs -5.59% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-53.4% (n=57) vs -6.6% (n=60) placebo @ 48wk50 mga,b,c,d
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more doses
-58% (n=55) vs -6.6% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-31.4% (n=54) vs -6.6% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
HDL-C
percent change · % of baseline
57.43% (n=57) vs 10.53% (n=39) placebo @ 52wk80 mga,b,c,d
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more dose
54.2% (n=58) vs 10.53% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
37.8% (n=57) vs 6.1% (n=60) placebo @ 48wk50 mga,b,c,d
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more doses
32.4% (n=55) vs 6.1% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
23.5% (n=54) vs 6.1% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Non-HDL-C
percent change · % of baseline
-26.57% (n=57) vs -2.55% (n=39) placebo @ 52wk80 mga,b,c,d
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more dose
-20% (n=58) vs -2.55% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-13.5% (n=57) vs 0.5% (n=60) placebo @ 48wk50 mga,b,c,d
NCT04720534 · Phase 2 · registry result, not featured evidence
show 2 more doses
-23% (n=55) vs 0.5% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-10% (n=54) vs 0.5% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
Dropout rate
8.8%80 mge
NCT05355402 · Phase 2 · registry result, not featured evidence
show 5 more results
12.1%50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
0%50 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
13%15 mg Q2W
NCT03385239 · Phase 2 · registry result, not featured evidence
13.6%10 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
17.4%10 mg QW
NCT03385239 · Phase 2 · registry result, not featured evidence
7%50 mge
NCT04720534 · Phase 2 · registry result, not featured evidence
show 6 more results
5.5%25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
9.1%10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
7.6%50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
7.6%50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
4.5%25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
10.4%10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—80 mge
NCT05355402 · Phase 2 · registry result, not featured evidence
show 5 more results
—50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
0%50 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
4.3%15 mg Q2W
NCT03385239 · Phase 2 · registry result, not featured evidence
0%10 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
0%10 mg QW
NCT03385239 · Phase 2 · registry result, not featured evidence
1.8%50 mge
NCT04720534 · Phase 2 · registry result, not featured evidence
show 6 more results
0%25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
1.8%10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
0%50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
1.5%50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
0%25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
1.5%10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
Serious AEs
14%80 mge
NCT05355402 · Phase 2 · registry result, not featured evidence
show 5 more results
10.3%50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
13.6%50 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
17.4%15 mg Q2W
NCT03385239 · Phase 2 · registry result, not featured evidence
13.6%10 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
4.3%10 mg QW
NCT03385239 · Phase 2 · registry result, not featured evidence
12.5%50 mge
NCT04720534 · Phase 2 · registry result, not featured evidence
show 6 more results
3.6%25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
7.4%10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
10.6%50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
7.6%50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
7.5%25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
3%10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
80 mge
covid-19 7% (placebo 5.1%)
diabetes mellitus 7% (placebo 2.6%)
acute sinusitis 5.3% (placebo 2.6%)
NCT05355402 · Phase 2 · registry result, not featured evidence
show 5 more results
50 mg
injection site erythema 13.8% (placebo 0%)
fatigue 10.3% (placebo 2.6%)
urinary tract infection 10.3% (placebo 15.4%)
NCT05355402 · Phase 2 · registry result, not featured evidence
50 mg Q4W
injection site erythema 18.2% (placebo 0%)
nasopharyngitis 18.2% (placebo 12.5%)
nausea 18.2% (placebo 4.2%)
NCT03385239 · Phase 2 · registry result, not featured evidence
15 mg Q2W
nasopharyngitis 17.4% (placebo 12.5%)
arthralgia 13% (placebo 0%)
dizziness 13% (placebo 0%)
NCT03385239 · Phase 2 · registry result, not featured evidence
10 mg Q4W
anaemia 13.6% (placebo 0%)
arthralgia 13.6% (placebo 0%)
back pain 13.6% (placebo 4.2%)
NCT03385239 · Phase 2 · registry result, not featured evidence
10 mg QW
injection site erythema 21.7% (placebo 0%)
nasopharyngitis 21.7% (placebo 12.5%)
upper respiratory tract infection 17.4% (placebo 12.5%)
NCT03385239 · Phase 2 · registry result, not featured evidence
50 mge
covid-19 16.1% (placebo 14.8%)
upper respiratory tract infection 12.5% (placebo 6.6%)
type 2 diabetes mellitus 10.7% (placebo 4.9%)
NCT04720534 · Phase 2 · registry result, not featured evidence
show 6 more results
25 mg
covid-19 16.4% (placebo 14.8%)
headache 10.9% (placebo 4.9%)
sinusitis 7.3% (placebo 0%)
NCT04720534 · Phase 2 · registry result, not featured evidence
10 mg
covid-19 20.4% (placebo 14.8%)
headache 14.8% (placebo 4.9%)
urinary tract infection 11.1% (placebo 9.8%)
NCT04720534 · Phase 2 · registry result, not featured evidence
50 mg Q12W
covid-19 13.6% (placebo 13.8%)
type 2 diabetes mellitus 12.1% (placebo 4.6%)
urinary tract infection 9.1% (placebo 8%)
NCT04998201 · Phase 2 · registry result, not featured evidence
50 mg Q24W
type 2 diabetes mellitus 16.7% (placebo 4.6%)
upper respiratory tract infection 13.6% (placebo 8%)
covid-19 9.1% (placebo 13.8%)
NCT04998201 · Phase 2 · registry result, not featured evidence
25 mg Q12W
covid-19 16.4% (placebo 13.8%)
upper respiratory tract infection 10.4% (placebo 8%)
urinary tract infection 9% (placebo 8%)
NCT04998201 · Phase 2 · registry result, not featured evidence
10 mg Q12W
covid-19 11.9% (placebo 13.8%)
type 2 diabetes mellitus 7.5% (placebo 4.6%)
bronchitis 6% (placebo 1.1%)
NCT04998201 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 48 weeks versus 52 weeks.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olezarsen

Fasting TG Less Than 150 mg/dL 84% (n=50) vs 11.4% (n=35) placebo @ 26wk80 mg
responder rate · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence
show 7 more results
82% (n=50) vs 5.7% (n=35) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
79.2% (n=53) vs 11.4% (n=35) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
69.8% (n=53) vs 5.7% (n=35) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
90.9% (n=22) vs 4.2% (n=24) placebo50 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
65.2% (n=23) vs 4.2% (n=24) placebo15 mg Q2W
NCT03385239 · Phase 2 · registry result, not featured evidence
13.6% (n=22) vs 4.2% (n=24) placebo10 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
73.9% (n=23) vs 4.2% (n=24) placebo10 mg QW
NCT03385239 · Phase 2 · registry result, not featured evidence
Remnant Cholesterol -59.59% (n=57) vs -9.46% (n=39) placebo @ 26wk80 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-66.9% (n=57) vs -14.83% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-55.98% (n=58) vs -9.46% (n=39) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-58.17% (n=58) vs -14.83% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Apo A1 14.91% (n=57) vs 2.84% (n=39) placebo @ 26wk80 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
15.46% (n=57) vs 0.81% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
17.37% (n=58) vs 2.84% (n=39) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
16.37% (n=58) vs 0.81% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Total Cholesterol -6.48% (n=57) vs 2.99% (n=39) placebo @ 26wk80 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-10.8% (n=57) vs -2.15% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-6.78% (n=58) vs 2.99% (n=39) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-6.08% (n=58) vs -2.15% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Fasting TG Less Than 500 mg/dL 100% (n=7) vs 75% (n=4) placebo @ 26wk80 mg
responder rate · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
100% (n=7) vs 75% (n=4) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
80% (n=5) vs 75% (n=4) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
100% (n=5) vs 75% (n=4) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Acute Pancreatitis 0% (n=57) vs 0% (n=39) placebo @ 52wk80 mg
event count · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 3 more results
0% (n=57) vs 0% (n=39) placebo @ 52wk*80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=58) vs 0% (n=39) placebo @ 52wk*50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=58) vs 0% (n=39) placebo @ 52wk*50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
Fasting TG Less Than 100 mg/dL 45.5% (n=22) vs 0% (n=24) placebo50 mg Q4W
responder rate · % of participants
NCT03385239 · Phase 2 · registry result, not featured evidence
show 3 more results
30.4% (n=23) vs 0% (n=24) placebo15 mg Q2W
NCT03385239 · Phase 2 · registry result, not featured evidence
0% (n=22) vs 0% (n=24) placebo10 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
26.1% (n=23) vs 0% (n=24) placebo10 mg QW
NCT03385239 · Phase 2 · registry result, not featured evidence
Fasting Triglycerides -55% @ 25.98wkolezarsen 80 mg
percent change · % of baseline
No placebo or comparator arm
NCT05610280 · Phase 3 · sponsor-reported, not registry data
show 5 more results
-72.2% @ 25.98wkolezarsen 80 mg
NCT05079919 · Phase 3 · sponsor-reported, not registry data
-54.5% @ 25.98wkolezarsen 80 mg
NCT05552326 · Phase 3 · sponsor-reported, not registry data
-49% @ 25.98wkolezarsen 50 mg
NCT05610280 · Phase 3 · sponsor-reported, not registry data
-62.9% @ 25.98wkolezarsen 50 mg
NCT05079919 · Phase 3 · sponsor-reported, not registry data
-49.2% @ 25.98wkolezarsen 50 mg
NCT05552326 · Phase 3 · sponsor-reported, not registry data

Plozasiran

Fasting TG -50.2% (n=64) vs 1.7% (n=85) placebo @ 48wk50 mg Q12W
percent change · % of baseline
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
show 3 more results
-55% (n=65) vs 1.7% (n=85) placebo @ 48wk50 mg Q24W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-42.8% (n=67) vs 1.7% (n=85) placebo @ 48wk25 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-33.2% (n=64) vs 1.7% (n=85) placebo @ 48wk10 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
Apo C3 -17.4% (n=64) vs 27.3% (n=84) placebo @ 48wk50 mg Q12W
percent change · % of baseline
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
show 3 more results
-64.8% (n=65) vs 27.3% (n=84) placebo @ 48wk50 mg Q24W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-13.9% (n=67) vs 27.3% (n=84) placebo @ 48wk25 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-31.2% (n=63) vs 27.3% (n=84) placebo @ 48wk10 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
Non-HDL-C -21.8% (n=64) vs 1.7% (n=85) placebo @ 48wk50 mg Q12W
percent change · % of baseline
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
show 3 more results
-20% (n=65) vs 1.7% (n=85) placebo @ 48wk50 mg Q24W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-12.1% (n=67) vs 1.7% (n=85) placebo @ 48wk25 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-12.1% (n=64) vs 1.7% (n=85) placebo @ 48wk10 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
HDL-C 34.3% (n=64) vs 4.5% (n=85) placebo @ 48wk50 mg Q12W
percent change · % of baseline
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
show 3 more results
44.5% (n=65) vs 4.5% (n=85) placebo @ 48wk50 mg Q24W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
30.5% (n=67) vs 4.5% (n=85) placebo @ 48wk25 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
25.4% (n=64) vs 4.5% (n=85) placebo @ 48wk10 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
Apo B -12.2% (n=64) vs 3.3% (n=84) placebo @ 48wk50 mg Q12W
percent change · % of baseline
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
show 3 more results
-11.9% (n=65) vs 3.3% (n=84) placebo @ 48wk50 mg Q24W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-6.4% (n=67) vs 3.3% (n=84) placebo @ 48wk25 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence
-4.7% (n=63) vs 3.3% (n=84) placebo @ 48wk10 mg Q12W
Change at Week 48/ET
NCT04998201 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olezarsen's landscape · Plozasiran's landscape